购物车
- 全部删除
- 您的购物车当前为空
CBL0137 (Curaxin 137) 是一种代谢稳定的 curaxin,可激活 p53 (EC50: 0.37 μM) 并抑制 NF-κB (EC50: 0.47 μM)。它在功能上使促进染色质转录复合物 (FACT) 失活,从而驱动对 p53 和 NF-κB 的影响并促进癌细胞死亡。口服 CBL0137 在小鼠体内具有广泛的抗癌活性,可根除耐药性癌症干细胞,并增强吉西他滨在胰腺癌临床前模型中的疗效。
CBL0137 (Curaxin 137) 是一种代谢稳定的 curaxin,可激活 p53 (EC50: 0.37 μM) 并抑制 NF-κB (EC50: 0.47 μM)。它在功能上使促进染色质转录复合物 (FACT) 失活,从而驱动对 p53 和 NF-κB 的影响并促进癌细胞死亡。口服 CBL0137 在小鼠体内具有广泛的抗癌活性,可根除耐药性癌症干细胞,并增强吉西他滨在胰腺癌临床前模型中的疗效。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 343 | 现货 | |
5 mg | ¥ 993 | 现货 | |
10 mg | ¥ 1,570 | 现货 | |
25 mg | ¥ 2,830 | 现货 | |
50 mg | ¥ 4,250 | 现货 | |
100 mg | ¥ 6,280 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 992 | 现货 |
产品描述 | CBL0137 (Curaxin 137), a metabolically stable curaxin, activates p53 (EC50: 0.37 μM) and inhibits NF-κB (EC50: 0.47 μM). It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death. CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates the efficacy of gemcitabine in preClinicalal models of pancreatic cancer. |
靶点活性 | NF-κB:0.47 μM (EC50), p53:0.37 μM (EC50) |
别名 | Curaxin 137, CBLC137 |
分子量 | 336.43 |
分子式 | C21H24N2O2 |
CAS No. | 1197996-80-7 |
Smiles | C(CNC(C)C)N1C=2C(C=3C1=CC=C(C(C)=O)C3)=CC(C(C)=O)=CC2 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 25 mg/mL (74.31 mM), Sonication is recommended. H2O: Insoluble | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容